Metastatic Prostate Cancer: In Search of More Granularity

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

(2019) Sarah Burdett et al.   EUROPEAN UROLOGY

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

(2019) Ian D. Davis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

(2019) Kim N. Chi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

(2019) N W Clarke et al.   ANNALS OF ONCOLOGY

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

(2018) Gwenaelle Gravis et al.   EUROPEAN UROLOGY

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

(2018) Christos E. Kyriakopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

(2018) Edoardo Francini et al.   PROSTATE

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

(2017) Karim Fizazi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

(2017) Nicholas D. James et al.   NEW ENGLAND JOURNAL OF MEDICINE